Every material Form 8-K PROKIDNEY CORP. has filed with the SEC since November 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ProKidney reported cash and marketable securities of $141.9 million as of September 30, 2026, in a filing that also furnished an updated investor presentation. The filing contains no revenue, net loss or per-share figures, so the cash balance and the company's stated runway are the main financial disclosures for shareholders.
Cash and marketable securities were $141.9 million as of September 30, 2026.
The updated investor presentation says current cash is expected to support operating plans into mid-2027.
The presentation lists the Phase 3 PROACT 1 topline readout for Q2 2027 and a BLA submission for Q1 2028.
The filing does not include revenue, net income or loss, or earnings per share.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every PROKIDNEY CORP. filing is on SEC EDGAR ↗. 8-K briefs of other companies →